🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against superbug strains of the bacteria, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are on the rise globally, with data suggesting in excess of 82 million infections each year. Especially elevated rates are seen in the African continent and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune step in the face of growing infection rates, the spread of superbugs and the very limited available drugs currently available.”

Health officials are increasingly worried about the surge in treatment-resistant strains. The global health body has designated it as a "critical concern". A tracking program found that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Receive Clearance

One new antibiotic, marketed under the name a brand name, was approved by the US FDA in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Scientists hope that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a new, not-for-profit approach for medication research. The charitable organization GARDP worked alongside the pharmaceutical company Innoviva to develop it.

“This approval marks a major breakthrough in the management of superbug gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

According to data published in a prominent scientific publication, the new drug cured over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which combines a dual-drug approach. The trial involved hundreds of participants from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, the non-profit has the ability to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals directly involved have expressed positive views. Access to a easy-to-administer therapy such as this is hailed as a "critical tool" for gonorrhoea control. This is considered essential to reduce the burden of the disease for patients and to halt the transmission of extremely resistant gonorrhoea globally.